Chronic spontaneous urticaria (CSU) is a skin disorder characterized by the recurring appearance of itchy wheals or hives that persist for more than six weeks without an identifiable cause.

Chronic Spontaneous Urticaria Market can significantly impact patients' quality of life, causing physical discomfort, emotional distress, and sleep disturbances. The condition affects approximately 1% of the general population, with women being more frequently affected than men.

According to CoherentMI, the chronic spontaneous urticaria market is estimated to be valued at USD 2.66 Bn in 2025 and is expected to reach USD 5.49 Bn by 2032, growing at a compound annual growth rate (CAGR) of 10.9% from 2025 to 2032.

Key Takeaways

Key players operating in the chronic spontaneous urticaria market are Novartis AG, Roche Holding AG, Pfizer Inc., Sanofi S.A., and Genentech Inc. These companies are focusing on developing novel therapies and targeted treatments for CSU, such as monoclonal antibodies and immunomodulators. Their research and development efforts aim to improve patient outcomes and capture a larger share of the market.

Get More Insights On:  Chronic Spontaneous Urticaria Market

Get this Report in Japanese Language: 慢性特発性蕁麻疹市場

Get this Report in Korean Language: 만성자발성두드러기시장